 |
 |
What is urate and how do you increase its level? ----- Original Message ----- From: "mschild" <[log in to unmask]> To: <[log in to unmask]> Sent: Wednesday, November 25, 2009 12:21 PM Subject: High Urate Means Slow PD Decline > High levels of urate in serum or cerebrospinal fluid are associated with > slower > rate of decline in Parkinson's disease, according to a new study. > > The authors evaluated urate from samples collected in the DATATOP study. > Patients were grouped into quintiles based on baseline urate > concentration. > Among all patients, those in the highest quintile (>6.2 mg/dL serum urate) > were less likely to progress to require levodopa therapy (the primary > endpoint > of DATATOP) compared to those in the lowest quintile (<3.9 mg/dL) > (p=0.02). > The trend for slower progression with higher urate across the 5 groups was > also significant. > > When stratified by vitamin E treatment (one of the treatment arms in the > study), the trend remained significant only for those patients not > receiving > vitamin E. Selegiline treatment did not affect the trend. > > As with serum urate, higher CSF urate also correlated with slower > progression, > but only in patients not receiving vitamin E. > > "Taken together, these data establish urate as the first molecular > predictor of > clinical progression in PD," the authors conclude, "and provide a > rationale > for investigating the possibility that a therapeutic increase of urate in > patients with PD might act favorably to slow the disease course." > > They also note their data raise the possibility that an interaction > between > urate and vitamin E "may have obscured a protective effect [of vitamin E] > among > those subjects with low baseline concentrations of urate in the DATATOP > trial," and suggest it may be worth investigating whether vitamin E is > useful > in those with low urate. > > Urate as a clinical predictor of the rate of clinical decline in Parkinson > disease > A Ascherio, P LeWitt, K Xu, S Eberly, A Watts, WR Mason, C Marras, K > Kieburtz, > A Rudolph, MB Bogdanov, SR Schwid, M Tennis, CM Tanner, MF Beal, AE Lang, > D > Oakes, S Fahn, I Shoulson, MA Schwarzschild, PSG Datatop Investigators > Arch Neurol, 2009;66:published online 12 October 2009 > Doi:10.1001/archneurol.2009.247 > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: > mailto:[log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn